MetaCap

Bolt Biotherapeutics (BOLT) vs MIRA Pharmaceuticals (MIRA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Bolt Biotherapeutics is the larger company by market cap ($12.8 million vs $12.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BOLT+36.39%MIRA-59.01%
+90%+12%-66%
Oct 7, 20261 yearNov 20, 2026
BOLT+19.46%MIRA-60.97%
+66%-0%-67%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BOLT versus MIRA key metrics
MetricBOLTMIRA
Share price$4.91$0.291
Market cap$12.80M$12.23M
1-day change-2.96%-20.84%
YTD return—-80.73%
1-year return—-79.06%
P/E ratio (TTM)—29.10
EPS (TTM)$-14.00$0.01
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$7.70M—
Revenue growth (YoY)+0.07%—
Net income (latest FY)$-33.38M$-10.44M
Operating margin-469.30%—
Net margin-433.74%—
52-week high$7.78$1.69
52-week low$3.10$0.255
Distance from 52-week high-36.89%-82.78%
Analyst consensusnonenone
Avg. price target upside+490.63%+1102.75%
Average volume257.43K622.02K
Shares outstanding2.61M42.02M
Employees23—
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Bolt Biotherapeutics

BOLT stock →

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; CEA ISAC, a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 for the treatment of solid tumors, including colorectal, non-small cell lung, pancreatic, and breast; and PD-L1 ISAC, a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker to target both tumor and immune cells for the treatment of tumor regression and immunological memory.

Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees

About MIRA Pharmaceuticals

MIRA stock →

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders.

Health Care · Biotechnology: Pharmaceutical Preparations

BOLT vs MIRA FAQ

Which is bigger, Bolt Biotherapeutics or MIRA Pharmaceuticals?

Bolt Biotherapeutics (BOLT) is larger, with a market capitalization of $12.80M compared with $12.23M for MIRA Pharmaceuticals (MIRA).

Are Bolt Biotherapeutics and MIRA Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons